Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.74 |
| ▸ | NAAA | Q02083 | 1/20 | 0.69 |
| ▸ | FAAH | O00519 | 5/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.53 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28420676 | 1.00 | CASP2 (0.74) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL937406 | 1.00 | CASP2 (0.74) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL2048941 | 0.98 | CASP2 (0.70) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL295180 | 0.92 | CASP2 (0.61) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL5539151 | 0.90 | CASP2 (0.71) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL7557154 | 0.89 | CASP2 (0.69) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL10895513 | 0.89 | CASP2 (0.69) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL10443771 | 0.89 | CASP2 (0.69) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL7558317 | 0.89 | CASP2 (0.69) | CASP2NAAAFAAHEPHX1DNM1 | |
| SCHEMBL5541786 | 0.89 | CASP2 (0.69) | CASP2NAAAFAAHEPHX1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CASP2 2099/4885NAAA 2414/4885FAAH 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.